Sorrento Therapeutics Inc (SRNE)

[dia76ca]

Important thoughts by Robert...
"We had 2 significant PR's and while the STIX approval in Mexico was a nice "monkey off our backs" moment-- the closing of ACEA was even bigger. Abivertinib as our "Franchise Molecule" and the foundation for the creation of a "Major Oncology Franchise"-- has tremendous potential to be a first and second line treatment option for numerous indications in NSCLC, prostate cancer, multiple sclerosis, systemic lupus, and hairy cell leukemia-- which the latter has already been granted an orphan drug designation from the FDA.

There were also 2 new trials posted today for MSC that show Sorrento is going all in on MSC and must be confident in their ability to manufacture and scale-- which Ji is still holding that particular card very close.

MSC for non-COVID ARDS is huge as we've discussed multiple times but now we have confirmation that they are indeed moving forward with this. The other P2 MSC trial posted was for COVID long haul syndrome-- specifically those that continue to have breathing issues post recovery. This particular subset of COVID long haulers are dealing with the remaining scar tissue left in their lungs once the virus has been eliminated from their body. If these trials are successful this will show that MSC has the ability to reverse and repair the scarred lung tissue. MSC as regenerative medicine will unlock the gates to a plethora of new indications and the acceleration of what I believe is an inevitable paradigm shift to cellular medicine-- from both a regulatory and industry perspective. You can bet Dr. Hariri of Celularity is paying very close attention to these MSC trials.

The strategy is unreal and their ability to potentially corner the COVID long haul market with both SP-104 (ARD-301) and now MSC is huge. Add to that MSC as a life-saving rescue treatment/cure for all things ARDS. The ability to take both these candidates to a greater reach for huge unmet needs outside of COVID for both non-COVID ARDS and chronic pain/fibromyalgia coupled with the ACEA Oncology Franchise will be the foundation for a juggernaut BP.

Toss in STIX, TRACK, DROPS, ADNIC/ADNAB, SmartPharm, Scilex, CAR/DAR-T, several P3 completed biosimilar/biobetters, and the G-Mab library to that foundation. Oh, did I mention RTX??? The future is bright folks. Long and strong!"

Rows 12 and 13:

https://clinicaltrials.gov/ct2/results?cond=&term=sorrento&cntry=&state=&city=&dist=